Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2018

Nov 06, 2018

SELL
$8.6 - $11.26 $1,178 - $1,542
-137 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$5.07 - $7.92 $694 - $1,085
137
137 $1,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Gryphon Financial Partners LLC Portfolio

Follow Gryphon Financial Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gryphon Financial Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gryphon Financial Partners LLC with notifications on news.